P. Rougier
- Oncology top 0.2%
- Colorectal Cancer Treatments and Studies 53
- Cancer Treatment and Pharmacology 25
- Pancreatic and Hepatic Oncology Research 19
- Hepatology top 0.5%
- Hepatocellular Carcinoma Treatment and Prognosis 20
- Gastroenterology top 0.5%
- Pulmonary and Respiratory Medicine top 0.5%
- Gastric Cancer Management and Outcomes 21
- Lung Cancer Treatments and Mutations 18
- Surgery top 1%
-
- Neuroendocrine Tumor Research Advances 14
-
- Metallic Glasses and Amorphous Alloys 14
P. Rougier
114 papers receiving 7.8k citations
Hit Papers
Peers
Comparison fields: 5 of 132
- Oncology 5.4k
- Hepatology 1.2k
- Gastroenterology 789
- Pulmonary and Respiratory Medicine 3.3k
- Surgery 2.4k
Countries citing papers authored by P. Rougier
This map shows the geographic impact of P. Rougier's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Rougier with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Rougier more than expected).
Fields of papers citing papers by P. Rougier
This network shows the impact of papers produced by P. Rougier. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Rougier. The network helps show where P. Rougier may publish in the future.
Co-authorship network
The 25 scholars most cited alongside P. Rougier, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2016 | 55 | |
| 2 | 2014 | 3 | |
| 3 | 2014 | 1 | |
| 4 | 2014 | 88 | |
| 5 | 2013 | 4 | |
| 6 | 2012 | 57 | |
| 7 | 2012 | 281 | |
| 8 | Perioperative Chemotherapy Compared With Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trialbreakdown → | 2011 | 1484 |
| 9 | 2011 | 14 | |
| 10 | 2010 | 5 | |
| 11 | 2009 | 254 | |
| 12 | Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for locally advanced unresectable pancreatic cancer. Definitive results of the 2000–01 FFCD/SFRO studybreakdown → | 2008 | 501 |
| 13 | 2006 | 68 | |
| 14 | 2005 | 107 | |
| 15 | 2004 | 20 | |
| 16 | 2003 | 96 | |
| 17 | 2002 | 78 | |
| 18 | 2001 | 2 | |
| 19 | 2000 | 74 | |
| 20 | 1997 | 46 |
About P. Rougier
P. Rougier is a scholar working on Oncology, Hepatology, Pulmonary and Respiratory Medicine, Pathology and Forensic Medicine and Gastroenterology, having authored 115 papers that have together received 8.0k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (53 papers), Cancer Treatment and Pharmacology (25 papers), Gastric Cancer Management and Outcomes (21 papers), Hepatocellular Carcinoma Treatment and Prognosis (20 papers), Pancreatic and Hepatic Oncology Research (19 papers), Lung Cancer Treatments and Mutations (18 papers), Neuroendocrine Tumor Research Advances (14 papers) and Metallic Glasses and Amorphous Alloys (14 papers). The work is most often cited by research in Oncology (5.4k citations), Hepatology (1.2k citations), Gastroenterology (789 citations), Pulmonary and Respiratory Medicine (3.3k citations) and Surgery (2.4k citations). P. Rougier has collaborated with scholars based in France, Belgium and Germany. Frequent co-authors include Eric Van Cutsem, P Lasser, Olivier Bouché, Marc Ychou, Laurent Bedenne, Emmanuel Mitry, Michel Ducreux, Valérie Boige, Jean‐Pierre Pignon and G. Lebreton. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, British Journal of Cancer, European Journal of Cancer and Journal of Magnetism and Magnetic Materials.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.